Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296321 | 0.78 | GAA (0.39) | KDM4EALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL1650805 | 0.78 | SMN1; SMN2 (0.37) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28838489 | 0.69 | KDM4E (0.34) | KDM4EALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL29428732 | 0.69 | KDM4E (0.34) | KDM4EALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL30859014 | 0.69 | MAPT (0.41) | KDM4ERPS6KA5 | |
| SCHEMBL23290833 | 0.69 | ADORA3 (0.37) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL860168 | 0.68 | KDM4E (0.32) | KDM4EALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL2783602 | 0.68 | ALDH1A1 (0.48) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1558803 | 0.68 | DYRK1A (0.50) | SMN1; SMN2 | |
| SCHEMBL21162587 | 0.68 | IKBKB (0.39) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805280-B | Heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-12-06 | — | — | CN | disclosed |
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3814345-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210252175-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | AC IMMUNE SA (CH) | 2021-08-19 | — | — | US | disclosed |
| CN-112805280-A | Heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-3814345-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | KDM4E 3075/4885ALDH1A1 1911/4885SMN1; SMN2 224/4885 |
| US-20210252175-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | SNCA, PARK7, NLN | KDM4E 4492/4885ALDH1A1 2495/4885SMN1; SMN2 97/4885 |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | KDM4E 3075/4885ALDH1A1 1911/4885SMN1; SMN2 224/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | KDM4E 4065/4885ALDH1A1 3080/4885SMN1; SMN2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.